drugset / Trial / NCT05319431
A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of AK104 plus lenvatinib combined with on-demand TACE in participants with unresectable, non-metastatic hepatocellular carcinoma
Timeline
- Start
- 2022-06-28
- Primary completion
- 2023-08-15
- Completion
- 2025-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cadonilimab | Monoclonal antibody | — | Intravenous |
| Subject | Lenvatinib | Small molecule | 8 mg | Oral |
| Subject | Lenvatinib | Small molecule | 12 mg | Oral |